Does Aspirin Reduce the Risk of Invasive Melanoma in Older Adults?

Source: Cancer Therapy Advisor, March 2022

A randomized trial showed no significant difference in the rate of invasive melanoma between patients taking daily aspirin and those taking a placebo.

However, researchers said these results don’t rule out the possibility that aspirin might have a chemopreventive effect on melanoma incidence.

The results, from the ASPREE trial, were published in Cancer Prevention Research.

The trial (ClinicalTrials.gov Identifier:  NCT01038583) enrolled 19,114 adults — 16,703 from Australia and 2411 from the United States. Patients were randomly assigned to receive aspirin at 100 mg daily (n=9525) or placebo (n=9589).

READ THE ORIGINAL FULL ARTICLE